Status:
TERMINATED
Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use
Lead Sponsor:
AstraZeneca
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
This post marketing surveillance study aims to monitor the safety and efficacy of ONGLYZA under conditions of actual use in patients who are diagnosed with diabetes mellitus type 2 and are prescribed ...
Eligibility Criteria
Inclusion
- Diagnosis of Type 2 Diabetes Mellitus
- Prescribed Saxagliptin by patient's attending physician
Exclusion
- Known allergic or serious adverse reaction to Saxagliptin
- Pregnant or breastfeeding patients
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
542 Patients enrolled
Trial Details
Trial ID
NCT01223456
Start Date
October 1 2010
End Date
December 1 2012
Last Update
October 8 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Batangas, Batangas, Philippines
2
Research Site
Cebu City, Cebu, Philippines
3
Research Site
Davao City, Davao Region, Philippines
4
Research Site
Iloilo City, Iloilo, Philippines